Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4788980
Max Phase: Preclinical
Molecular Formula: C23H29FN4O2
Molecular Weight: 412.51
Molecule Type: Unknown
Associated Items:
ID: ALA4788980
Max Phase: Preclinical
Molecular Formula: C23H29FN4O2
Molecular Weight: 412.51
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CCN(CC)CCCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Standard InChI: InChI=1S/C23H29FN4O2/c1-5-28(6-2)11-7-10-25-23(30)21-14(3)20(26-15(21)4)13-18-17-12-16(24)8-9-19(17)27-22(18)29/h8-9,12-13,26H,5-7,10-11H2,1-4H3,(H,25,30)(H,27,29)/b18-13-
Standard InChI Key: MLSDVCJXCYFKAJ-AQTBWJFISA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 412.51 | Molecular Weight (Monoisotopic): 412.2275 | AlogP: 3.73 | #Rotatable Bonds: 8 |
Polar Surface Area: 77.23 | Molecular Species: BASE | HBA: 3 | HBD: 3 |
#RO5 Violations: 0 | HBA (Lipinski): 6 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 11.47 | CX Basic pKa: 9.83 | CX LogP: 2.84 | CX LogD: 0.58 |
Aromatic Rings: 2 | Heavy Atoms: 30 | QED Weighted: 0.46 | Np Likeness Score: -1.16 |
1. Matheson CJ,Casalvieri KA,Backos DS,Minhajuddin M,Jordan CT,Reigan P. (2020) Substituted oxindol-3-ylidenes as AMP-activated protein kinase (AMPK) inhibitors., 197 [PMID:32334266] [10.1016/j.ejmech.2020.112316] |
Source(1):